Is PT-141 (Bremelanotide) Legal in Michigan?

What Exactly Is PT-141 (Bremelanotide)?

PT-141 is the research name for bremelanotide, a cyclic heptapeptide that acts on melanocortin receptors in the central nervous system rather than on vascular smooth muscle. That mechanism separates it from phosphodiesterase-5 inhibitors such as sildenafil. The FDA approved the branded subcutaneous formulation Vyleesi in June 2019 specifically for HSDD in premenopausal women. [1]

Mechanism of Action

Bremelanotide binds preferentially to MC4R and MC3R in the hypothalamus. Activation of those receptors appears to increase sexual motivation through dopaminergic pathways. A 2014 Phase 2 study published in the Journal of Sexual Medicine (N=397) reported statistically significant improvements in desire and distress scores compared with placebo. [2]

Approved Indication vs. Off-Label Use

The on-label use is narrowly defined: acquired, generalized HSDD in premenopausal women. Prescribers in Michigan, like those anywhere in the United States, may legally prescribe any approved drug off-label based on clinical judgment. Off-label uses documented in the literature include male sexual dysfunction and postmenopausal women, though the evidence base for those populations is smaller. [3]

Federal Legal Status: FDA Approval and DEA Scheduling

PT-141 is not a gray-area research chemical. Bremelanotide holds full FDA new drug application (NDA) approval under NDA 210557. [1] The Drug Enforcement Administration has not placed it on any controlled substance schedule, meaning it carries no federal Schedule I through V designation. [4]

FDA NDA 210557 and What It Means

Approval under NDA 210557 means bremelanotide met the FDA's standards for safety and efficacy through placebo-controlled Phase 3 trials. The RECONNECT trials (two identically designed studies, combined N=1,247) showed that women using Vyleesi reported a statistically significant increase in satisfying sexual events and a reduction in HSDD-related distress compared with placebo (P<0.001 for distress reduction in both studies). [5]

No DEA Scheduling

Because bremelanotide is not scheduled, prescribers do not need a DEA-X waiver or any special federal registration to prescribe it. A standard DEA registration is sufficient. Pharmacies fill it under normal prescription drug procedures.

Michigan State Law: No Additional Restrictions

Michigan does not have a state-specific statute that further restricts bremelanotide beyond the federal prescription drug framework. The Michigan Public Health Code (MCL 333.7101 et seq.) governs controlled substances, and bremelanotide is not listed there. The Michigan Board of Pharmacy regulates prescription drugs under MCL 333.17701 et seq., requiring a valid prescriber-patient relationship for any legend drug dispensed in the state. [6]

The Prescriber-Patient Relationship Requirement

Michigan law requires that a prescriber establish a legitimate medical relationship before issuing any prescription. For telehealth encounters, Michigan's telehealth statute (MCL 333.16285) allows remote prescribing when the prescriber meets the same standard of care required in person. That means a telehealth visit with a Michigan-licensed physician, nurse practitioner, or physician assistant can legally result in a bremelanotide prescription if the clinical criteria are met. [7]

Michigan Board of Pharmacy Rules on Compounded Peptides

Compounded bremelanotide occupies a distinct legal niche from the branded Vyleesi auto-injector. Michigan 503A pharmacies (traditional compounding pharmacies) may prepare patient-specific bremelanotide preparations when a licensed prescriber submits a valid prescription. The federal compounding framework under 21 U.S.C. 503A permits this as long as the drug is not on the FDA's "Difficult to Compound" list and the compounded preparation is not essentially a copy of the commercially available product. [8]

The practical implication: a Michigan patient who cannot tolerate the auto-injector device, needs a dose different from 1.75 mg, or faces cost barriers may receive a compounded bremelanotide preparation from an appropriately licensed 503A pharmacy in Michigan or from an out-of-state 503A pharmacy shipping into Michigan, provided all state shipping and labeling requirements are met.

503A vs. 503B Compounding: What Michigan Patients Need to Know

503A Pharmacies (Patient-Specific Compounding)

A 503A pharmacy compounds drugs for individual patients based on a specific prescription. These pharmacies are regulated primarily by state pharmacy boards. The Michigan Board of Pharmacy requires 503A compounders to comply with USP 795 (non-sterile) or USP 797 (sterile) standards. Bremelanotide is typically compounded as a sterile injectable or nasal spray, so USP 797 applies. [9]

The FDA's guidance on 503A compounding states that a compounded drug may not be a "copy" of an FDA-approved drug when the approved drug is commercially available and meets the patient's clinical need. [8] Prescribers who want to justify compounded bremelanotide should document the clinical rationale (dose adjustment, delivery method, excipient allergy) in the patient's chart.

503B Outsourcing Facilities

503B outsourcing facilities produce larger batches without patient-specific prescriptions. The FDA publishes lists of bulk drug substances that 503B facilities may or may not use. As of July 2025, bremelanotide does not appear on the FDA's Category 1 (approved for 503B use) or Category 2 (under evaluation) bulk drug substance lists. [10] That limits 503B sourcing significantly. Most legal compounded bremelanotide in Michigan flows through 503A pharmacies, not 503B outsourcing facilities.

What This Means Practically

If a Michigan telehealth platform or clinic directs you to a 503B outsourcing facility for bremelanotide, ask for documentation that the facility holds current FDA registration and that bremelanotide is on an approved bulk substance list. Absence of that documentation is a compliance red flag.

How to Get PT-141 (Bremelanotide) Legally in Michigan

Getting bremelanotide legally in Michigan requires four steps: a clinical evaluation, a diagnosis or documented off-label rationale, a valid prescription, and a licensed pharmacy. Each step has regulatory substance, not just bureaucratic formality.

Step 1: Clinical Evaluation

A licensed Michigan prescriber must assess whether HSDD (or another documented indication) is present. For women, validated tools include the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R). The RECONNECT trials used a score of <26.55 on the FSFI and >11 on the FSDS-R as inclusion criteria. [5] A prescriber documenting similar baseline scores creates a defensible record if a pharmacy or insurer questions the prescription.

Step 2: Rule Out Contraindications

The FDA label for Vyleesi lists cardiovascular disease as a contraindication because bremelanotide transiently increases blood pressure (mean increase of 6 mmHg systolic, 3 mmHg diastolic, peaking at 4 hours post-dose in Phase 3 data). [1] Patients with uncontrolled hypertension or known cardiovascular disease should not use it. Michigan prescribers should document a blood pressure reading and relevant cardiac history before issuing the prescription.

Step 3: Obtain the Prescription

The prescription may come from a Michigan-licensed physician (MD or DO), advanced practice registered nurse (APRN) with prescriptive authority, or physician assistant (PA) operating within their collaborative agreement. Telehealth visits that meet Michigan's standard-of-care requirement are legally equivalent to in-person visits for this purpose. [7]

Step 4: Fill at a Licensed Pharmacy

Branded Vyleesi is available at retail and specialty pharmacies in Michigan that carry it. Compounded bremelanotide requires a 503A-licensed pharmacy. Check the Michigan Board of Pharmacy's license verification tool or the FDA's drug compounding website to confirm a pharmacy's standing before filling. [6, 10]

Branded Vyleesi vs. Compounded Bremelanotide: A Side-by-Side View

| Feature | Branded Vyleesi | Compounded Bremelanotide | |---|---|---| | FDA approval status | NDA 210557 approved | Not individually approved | | DEA schedule | None | None | | Legal in Michigan | Yes, with Rx | Yes, with Rx from 503A pharmacy | | Standard dose | 1.75 mg SC auto-injector | Flexible (prescriber-specified) | | Route options | Subcutaneous injection | SC injection or nasal spray | | Insurance coverage | Varies; prior auth common | Typically cash pay | | Quality oversight | FDA-inspected manufacturer | State board + USP 797 standard |

Who Qualifies? Clinical Criteria in Practice

The FDA-approved indication is specific: premenopausal women with acquired, generalized HSDD not caused by a co-existing medical or psychiatric condition, relationship distress, or medication side effects. "Acquired" means the condition developed after a period of normal function. "Generalized" means it occurs regardless of partner or situation. [1]

Off-Label Use in Men

Several small studies have examined bremelanotide for erectile dysfunction and male sexual desire disorder. A Phase 2 study (N=32) published in the Journal of Urology found that intranasal bremelanotide produced penile tumescence in men with psychogenic erectile dysfunction, though the intranasal route was discontinued due to emetic side effects in early development. [3] The subcutaneous formulation is now the standard, and off-label prescribing in men does occur in clinical practice. Michigan prescribers may write this off-label; the legal framework is the same.

Postmenopausal Women

HSDD is common after menopause, but the Vyleesi label does not cover postmenopausal women because the RECONNECT trials enrolled only premenopausal patients. Off-label prescribing is legally permissible in Michigan for a postmenopausal woman whose prescriber documents the clinical rationale.

Common Legal Pitfalls to Avoid in Michigan

Buying Without a Prescription

Purchasing bremelanotide without a valid prescription from any source, including online peptide vendors that sell to the general public, violates federal law (21 U.S.C. 331) and Michigan law (MCL 333.17751). The FDA has issued multiple warning letters to companies selling peptides without prescriptions. [11] Products sold as "research use only" carry no legal protection for personal use and have no quality verification.

Using Unregistered Compounding Pharmacies

Not every online pharmacy claiming to compound bremelanotide holds a valid Michigan or out-of-state license that permits shipping into Michigan. The National Association of Boards of Pharmacy (NABP) maintains a "Not Recommended" list of problematic online pharmacies. Cross-referencing a pharmacy's license before filling is a basic safety step. [12]

Telehealth Platforms Without Michigan Licensure

A prescriber must hold an active Michigan license to prescribe to Michigan residents, even via telehealth. Confirm that the platform assigns you to a Michigan-licensed clinician, not simply one licensed in another state.

Cost and Insurance Considerations

Branded Vyleesi carries a list price near $1,000 per 4-pack of auto-injectors, though manufacturer copay cards have reduced out-of-pocket costs significantly for commercially insured patients. Palatin Technologies and AMAG Pharmaceuticals' original patient support programs set copays as low as $99 per month for eligible patients. [1]

Compounded bremelanotide typically costs between $100 and $300 per vial depending on concentration and pharmacy, paid out of pocket because most insurers do not cover compounded drugs. Michigan Medicaid (Healthy Michigan Plan) does not list Vyleesi on its preferred drug list as of 2025, making prior authorization the norm for publicly insured patients.

What Michigan Prescribers Say About Bremelanotide in Practice

The North American Menopause Society (NAMS) 2022 position statement on sexual health states: "Bremelanotide is approved for the treatment of HSDD in premenopausal women and has demonstrated efficacy in improving sexual desire and reducing distress in randomized controlled trials." [13] That endorsement from a major specialty society gives Michigan prescribers clear guideline support for on-label use.

The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care consensus for HSDD identifies bremelanotide as a first-line pharmacologic option alongside flibanserin, noting that "the choice between agents should be individualized based on patient preference, comorbidities, and tolerability profile." [14]

Safety Profile: What Michigan Patients Should Know Before Starting

The most common adverse effects reported in RECONNECT trials were nausea (40% bremelanotide vs. 1% placebo), flushing (20% vs. 3%), and injection-site reactions (13% vs. 13%). [5] Nausea onset typically peaks at 1 hour post-injection and resolves within 12 hours. Prescribing an anti-emetic such as ondansetron 4 mg taken 30 minutes before the dose is a clinical strategy some providers use, though this is not in the FDA label.

Hyperpigmentation of the face, gums, or breasts may occur with repeated use, particularly in patients with darker skin tones. The FDA label recommends discontinuation if this occurs. [1]